KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)

CRISPR Therapeutics AG's Change in Receivables history spans 10 years, with the latest figure at -$25.0 million for Q1 2025.

  • For Q1 2025, Change in Receivables rose 87.5% year-over-year to -$25.0 million; the TTM value through Dec 2025 reached -$25.0 million, up 85.71%, while the annual FY2025 figure was -$25.0 million, 85.71% up from the prior year.
  • Change in Receivables for Q1 2025 was -$25.0 million at CRISPR Therapeutics AG, down from $25.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $200.0 million in Q4 2023 and bottomed at -$200.0 million in Q1 2024.
  • The 5-year median for Change in Receivables is -$17000.0 (2022), against an average of -$11076.9.
  • The largest YoY upside for Change in Receivables was 408263.27% in 2023 against a maximum downside of 411664.71% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $153000.0 in 2021, then plummeted by 132.03% to -$49000.0 in 2022, then surged by 408263.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024, then tumbled by 200.0% to -$25.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Change in Receivables are -$25.0 million (Q1 2025), $25.0 million (Q4 2024), and -$200.0 million (Q1 2024).